Bazedoxifene

Bazedoxifene

Clinical data
AHFS/Drugs.com	International Drug Names
License data	EU EMA: Conbriza
Routes of administration	Oral
ATC code	G03XC02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 1-{4-[2-(Azepan-1-yl)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol
CAS Number	198481-32-2 Y
PubChem CID	154257
IUPHAR/BPS	7355
DrugBank	DB06401 N
ChemSpider	135921 Y
UNII	Q16TT9C5BK
ChEMBL	CHEMBL46740 Y
PDB ligand	29S (PDBe, RCSB PDB)
ECHA InfoCard	100.232.728
Chemical and physical data
Formula	C30H34N2O3
Molar mass	470.603 g/mol
3D model (Jmol)	Interactive image
SMILES Oc1ccc(cc1)c3c(c2cc(O)ccc2n3Cc5ccc(OCCN4CCCCCC4)cc5)C
InChI InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3 Y Key:UCJGJABZCDBEDK-UHFFFAOYSA-N Y
NY (what is this?)

Bazedoxifene, or bazedoxifene acetate, is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. Bazedoxfiene is the result of an exclusive research collaboration between Wyeth Pharmaceuticals and Ligand Pharmaceuticals.

It is also being studied for possible treatment of breast cancer and pancreatic cancer.

As of December 2011, the FDA have not given approval for the use of bazedoxifene in the US.

The drug was approved in the European Union by the European Medicines Agency on April 27, 2009.

On October 3, 2013 the FDA approved the combination product of bazedoxifene 20 mg with 0.45 mg Premarin (conjugated estrogens) for the treatment of menopausal osteoporosis and the treatment of moderate to severe hot flushes. This is the first approved hormone replacement therapy product that contains a SERM (bazedoxifene) and an estrogen.